Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial.
Julie MankikianAgnès CailleMartine Reynaud-GaubertMarie-Sara AgierJulien BermudezPhilippe BonniaudRaphael BoriePierre-Yves BrilletJacques CadranelIsabelle Court-FortuneBruno CrestaniMarie-Pierre DebrayEmmanuel GomezAnne GondouinSandrine Hirschi-SantelmoDominique Israel-BietStéphane JouneauKarine JuvinJulie LegerMallorie KerjouanCharles Hugo MarquetteJean-Marc NaccacheHilario NunesLaurent PlantierGrégoire PrevotSébastien QuetantJulie TracletVictor ValentinYurdagul UzunhanLidwine Wémeau-StervinouTheodora Bejan-AngoulvantVincent CottinSylvain Marchand-Adamnull nullPublished in: The European respiratory journal (2023)
Combination of rituximab and MMF was superior to MMF alone in patients with ILD and a NSIP pattern. The use of this combination must consider the risk of viral infection.